Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,215,078 papers from all fields of science
Search
Sign In
Create Free Account
KRN 5500
Known as:
6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-beta-L-mannohepto-pyranosyl]amino-9H-purine
, KRN-5500
, KRN5500
A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Cell Differentiation process
Endoplasmic Reticulum
Golgi Apparatus
Positive Regulation of Apoptosis
Expand
Broader (1)
Purine Nucleosides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
S. Weinstein
,
A. Abernethy
,
S. Spruill
,
I. Pike
,
Andrea True Kelly
,
L. G. Jett
Journal of Pain and Symptom Management
2012
Corpus ID: 36117962
2003
2003
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
J. Byrd
,
D. Lucas
,
A. Mone
,
Joshua B. Kitner
,
J. Drabick
,
M. Grever
Blood
2003
Corpus ID: 121446
Therapy of B-cell chronic lymphocytic leukemia (CLL) is currently palliative, emphasizing the need for identification of new…
Expand
2003
2003
A Single Intravenous Injection of KRN5500 (Antibiotic Spicamycin) Produces Long-Term Decreases in Multiple Sensory Hypersensitivities in Neuropathic Pain
L. Kobierski
,
S. Abdi
,
L. DiLorenzo
,
N. Feroz
,
D. Borsook
Anesthesia and Analgesia
2003
Corpus ID: 46376083
Neuropathic pain is a significant clinical problem. Currently, there are no drugs that produce complete amelioration of this type…
Expand
2002
2002
Incorporation of the Anticancer Agent KRN5500 into Polymeric Micelles Diminishes the Pulmonary Toxicity
Y. Mizumura
,
Y. Matsumura
,
+4 authors
T. Kakizoe
Japanese journal of cancer research : Gann
2002
Corpus ID: 13714937
KRN5500 is a highly active new semi‐synthetic water‐insoluble anticancer agent. The only mechanism of anticancer activity of…
Expand
2001
2001
Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study
H. Takama
,
Hideji Tanaka
,
Tomohiro Sudo
,
T. Tamura
,
Y. Tanigawara
Cancer Chemotherapy and Pharmacology
2001
Corpus ID: 21399511
Abstract. Purpose: KRN5500, a novel spicamycin derivative, shows the greatest activity against a human tumor xenograft model and…
Expand
2000
2000
The Effects of KRN5500, a Spicamycin Derivative, on Neuropathic and Nociceptive Pain Models in Rats
S. Abdi
,
N. Vilassova
,
I. Decosterd
,
N. Feroz
,
D. Borsook
Anesthesia and Analgesia
2000
Corpus ID: 28679774
We studied the effects of a spicamycin derivative, KRN5500, on two animal models of neuropathic pain (Chung and Bennett models…
Expand
Highly Cited
1999
Highly Cited
1999
Reduction of the Side Effects of an Antitumor Agent, KRN5500, by Incorporation of the Drug into Polymeric Micelles
Y. Matsumura
,
M. Yokoyama
,
+4 authors
T. Kakizoe
Japanese journal of cancer research : Gann
1999
Corpus ID: 13712215
For intravenous (i.v.) injection of a water‐insoluble antitumor drug, KRN5500, we have successfully incorporated KRN5500 into…
Expand
1997
1997
Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.
A. Burger
,
G. Kaur
,
+5 authors
E. Sausville
Clinical Cancer Research
1997
Corpus ID: 882567
The spicamycin analogue KRN5500 (NSC 650426; SPA) is derived from Streptomyces alanosinicus. The unique structure contains a…
Expand
1995
1995
In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Y. Lee
,
K. Nishio
,
H. Ogasawara
,
Y. Funayama
,
T. Ohira
,
N. Saijo
Cancer Research
1995
Corpus ID: 7816526
Spicamycin (SPM), produced by Streptomyces alanosinicus, induces potent differentiation in a human leukemia cell line, HL60. One…
Expand
1994
1994
Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
M. Kamishohara
,
H. Kawai
,
+7 authors
T. Tsuruo
Oncology Research
1994
Corpus ID: 10673654
KRN5500, (6-[4-Deoxy-4-(2E,4E)-tetradecadienoylglycyl]amino-L-glycero - beta-L-mannoheptopyranosyl]amino-9H-purine), was semi…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE